<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849237</url>
  </required_header>
  <id_info>
    <org_study_id>RuMCeSS</org_study_id>
    <nct_id>NCT01849237</nct_id>
  </id_info>
  <brief_title>Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia</brief_title>
  <official_title>Russian Single-center Open Randomized Clinical Trial of the Impact of Mesenchymal Stromal Cells Therapy on Organ Dysfunction and 28-day Mortality in Patients With Septic Shock and Severe Neutropenia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Hematology, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Center for Hematology, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock remains a significant clinical problem associated with high rates of mortality
      among neutropenic patient despite antimicrobial therapy and supportive care. Recently,
      mesenchymal stromal cells (MSC) have demonstrated remarkable potential effect in sepsis. MSC
      treatment significantly reduced mortality in septic mice receiving appropriate antimicrobial
      therapy. MSCs reduced systemic inflammatory cytokine levels in mice, down-regulated of
      inflammation and inflammation-related genes (such as interleukin-10, interleukin-6).
      Bacterial clearance was greater in MSC-treated mice. Thus, MSCs have beneficial effects on
      experimental sepsis and suggest that MSСs-therapy may be an effective adjunctive treatment to
      reduce sepsis-related mortality.

      The safety of MSCs is proved by Graft-versus-host disease treatment MSCs in patients after
      bone marrow transplantation.

      This study hypothesis is that MSCs reduce organ dysfunction/injury, systemic inflammation and
      mortality in patients with septic shock and severe neutropenia.

      The main goal of the study is to evaluate the impact of MSCs therapy on organ
      dysfunction/injury, systemic inflammation and 28-day mortality in patients with septic shock
      and severe neutropenia. All patients will be randomized in two groups: control group
      (standard treatment of septic shock) and MSCs-group (standard treatment of septic shock +
      MSCs infusion of 1-2 millions/kg/ day).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All activities related to this human subjects research have been guided by ethical principles
      and have been reviewed and approved Federalwide Assurance National Ctr for Hematology,
      FWA00006482. The goal of the trial is to evaluate plasma concentration of proinflammatory
      cytokine interleukin-6 and the antiinflammatory cytokine interleukin-10, plasma levels of
      blood creatinine, bilirubin, procalcitonin, C-reactive protein. Then we will evaluate
      requirement for renal replacement therapy, requirement for mechanical ventilation or
      non-invasive mechanical ventilation, pulmonary function-coefficient, partial oxygen pressure
      arterial blood level, electrocardiograms, Kaplan - Meier curve,28-days mortality.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of MSC therapy effects on organ dysfunction</measure>
    <time_frame>At Baseline and at day 2,3,7,14,21,28</time_frame>
    <description>Liver: levels of serum total bilirubin, transaminases, lactate dehydrogenase, plasma protrombin level
Pancreas: amylase level
Renal: number of hemodialysis/ hemodiafiltration, blood urea and creatinine levels
Pulmonary: requirement for mechanical ventilation or non-invasive mechanical ventilation, pulmonary function-coefficient, partial oxygen pressure arterial blood level
Cardiac: requirement for vasopressors, main parameters obtained from Transpulmonary Thermodilution- Systemic Vascular Resistance Index ( SVRI ), Cardiac Output (CO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of MSC therapy effects on systemic inflammatory parameters</measure>
    <time_frame>At Baseline and at day 2,3,7,14,21,28</time_frame>
    <description>plasma concentration of proinflammatory cytokine IL-6 and the antiinflammatory cytokine IL-10, concentration of procalcitonin, C-reactive protein Fibrinogen level, lactate level , the factor XII-dependent fibrinolytic activity blood routine examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of MSC therapy effects on septic shock reversal</measure>
    <time_frame>At Baseline and at day 2,3,7,14,21,28</time_frame>
    <description>SOFA score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Septic Shock</condition>
  <condition>Nonchemotherapy Drug-induced Neutropenia</condition>
  <condition>Neutropenia After Chemotherapy in Oncohematological Patients</condition>
  <condition>Neutropenia in Patients With Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Standard therapy of septic shock</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesenchymal stromal cells+ standard therapy of septic shock</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).
according to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Mesenchymal stromal cells</intervention_name>
    <description>MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).</description>
    <arm_group_label>Mesenchymal stromal cells+ standard therapy of septic shock</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard therapy of septic shock</intervention_name>
    <description>Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids</description>
    <arm_group_label>Standard therapy of septic shock</arm_group_label>
    <arm_group_label>Mesenchymal stromal cells+ standard therapy of septic shock</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        septic shock

        ≤10 hs after onset of septic shock severe neutropenia(≤ 1 10^9/l) Patients ≥17 years Signed
        Informed Consent to treatment

        Exclusion Criteria:

        oncohematological patients with resistance to chemotherapy Unsigned Informed Consent to
        treatment Age &gt;75 years; Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gennady M. Galstyan, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research center of Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gennady Galstyan, MD PhD</last_name>
    <phone>+7(495)6124859</phone>
    <email>gengalst@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Research Center for Hematology</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gennady M Galstyan, MD PhD</last_name>
      <phone>+7(495)6124859</phone>
      <email>gengalst@gmail.com</email>
    </contact>
    <investigator>
      <last_name>: Gennady M. Galstyan, , MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena N. Parovichnikova, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Polina M. Makarova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vyacheslav A. Novikov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irina V. Kolosova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanislav A. Keselman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandr Y. Mashkov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna V. Krechetova, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dmitri Tihomirov, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatiana A. Garanzha, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Larisa A. Kuzmina, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013 Feb;39(2):165-228. doi: 10.1007/s00134-012-2769-8. Epub 2013 Jan 30.</citation>
    <PMID>23361625</PMID>
  </reference>
  <reference>
    <citation>Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC, Stewart DJ. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 2010 Oct 15;182(8):1047-57. doi: 10.1164/rccm.201001-0010OC. Epub 2010 Jun 17.</citation>
    <PMID>20558630</PMID>
  </reference>
  <reference>
    <citation>Kebriaei P, Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy. 2011 Mar;13(3):262-8. doi: 10.3109/14653249.2010.549688. Epub 2011 Jan 13. Review.</citation>
    <PMID>21231805</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2013</study_first_posted>
  <last_update_submitted>May 8, 2013</last_update_submitted>
  <last_update_submitted_qc>May 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Center for Hematology, Russia</investigator_affiliation>
    <investigator_full_name>Elena N.Parovichnikova</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal Stromal Cells</keyword>
  <keyword>Septic Shock</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Procalcitonin</keyword>
  <keyword>Interleukin-6</keyword>
  <keyword>Interleukin-10</keyword>
  <keyword>C-reactive protein</keyword>
  <keyword>Survival</keyword>
  <keyword>Organ dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

